The FDA has approved Servier's vorasidenib for two forms of glioma, becoming the first targeted therapy for this aggressive and incurable form of brain cancer.
Pieris Pharmaceuticals’ long-standing immuno-oncology alliance with Servier is being dissolved after a clinical trial of the lead drug in the alliance revealed a safety concern.
The US FDA and EMA in the EU have started accelerated reviews of Servier’s vorasidenib for IDH-mutated low-grade glioma, which is vying to become the first targeted therapy for this a
Novartis’ position as the frontrunner in the race to bring a Tim3-targeting drug to market has been lost after it pulled a phase 3 trial of its sabatolimab candidate.
French pharma Servier has enlisted the aid of ‘digital twin’ specialist Aitia for a third time, adding a Parkinson’s disease project to their prior collaborations on pancr
The Paris Court of Appeals has handed down its judgment against Servier in the case involving its weight-loss therapy mediator, finding the company guilty of fraud and ord
In our final video from ESMO 2024, web editor Nicole Raleigh spoke with Dr Meredith McKean, a melanoma investigator at the Sarah Cannon Research Institute.